Clinical Outcome After Saphenous Vein Stenting With Taxus Liberté Stent Results From the OLYMPIA Registry (TAXUS Liberté Postapproval Global Program)

We evaluated the incidence of clinical events after implantation of the TAXUS Liberte paclitaxel-eluting stent in saphenous vein graft (SVG) lesions in an unselected patient population. The OLYMPIA (TAXUS Liberte Post-Approval Global Registry) program gathered data on 21 954 patients receiving at least 1 TAXUS Liberte stent, including 345 patients with SVG lesions. All cardiac events were monitored with independent adjudication of end points. Patients enrolled at procedure started with no mandated inclusion/exclusion criteria. In SVG-OLYMPIA (n = 345), baseline comorbidities/complex disease were more frequent than the rest of the OLYMPIA (n = 21 560). SVG-OLYMPIA had similar cardiac death, target vessel revascularization, and definitive stent thrombosis rates than the rest of OLYMPIA. Despite higher baseline risk, the SVG-OLYMPIA had similar 12-month clinical outcome than the rest of the OLYMPIA registry, confirming the safety and efficacy of the TAXUS Liberte stent in this high-risk group.